StreetAlpha.app
Home › Stocks › APRE

Aprea Therapeutics, Inc. (APRE)

$0.45
▲ +11.14%
LAST CLOSE · NOV 17

Aprea Therapeutics develops cancer drugs that target specific genetic mutations in tumors. It last closed at $0.45 on Nov 17, up 11.14% on the day.

AI Auto Pilots
Is APRE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$14.1M
EPS (diluted)
−$0.57
Valuation
Market cap
$6.4M
14.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$37.8M
At Sep 30
Shareholder equity
$34.1M
Shares outstanding
14.2M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$37.1M−$37.1MFY2021FY2022: −$112.7M−$112.7MFY2022FY2023: −$14.3M−$14.3MFY2023FY2024: −$13.0M−$13.0MFY2024FY2025: −$12.6M−$12.6MFY2025

From APRE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated APRE in the past 90 days, not enough for a consensus
Average 12-month target
$2.00
▲ 341.4% upside

Based on 1 analyst who set a price target on APRE in the past 90 days. The average target is $2.00, with a high of $2.00 and a low of $2.00, compared with the last close of $0.45.

Low $2.00Avg $2.00High $2.00
Blue marker: last close $0.45
Highest target$2.00
Average target$2.00
Lowest target$2.00
Latest rating changes
Ladenburg ThalmannInitiated
Oct 14Buy$2
WedbushMaintained
Aug 13Buy$3
OppenheimerInitiated
May 7Buy$5
DateFirmActionRatingPrice target
Oct 14Ladenburg ThalmannInitiatedBuy$2
Aug 13WedbushMaintainedBuy$3
May 7OppenheimerInitiatedBuy$5
Loading…

Technical Analysis

APRE · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 35% below its 50 day average. It is 62% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot at $0.43, and the nearest resistance the Pivot R1 at $0.48.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 11.6%/day
Key levels
$1.4952 week high+231.1%
$0.73200 day average+62.2%
$0.66100 day average+46.7%
$0.6150 day average+35.6%
$0.53Swing high (Nov 9)+17.8%
$0.4920 day average+8.9%
$0.48Pivot R1+6.7%
$0.45Last close
$0.43Pivot−4.4%
$0.41Pivot S1−8.9%
$0.41Swing low (Oct 26)−8.9%
$0.3952 week low−13.3%
Indicators
RSI (14)40.33Middle of its rangeNeutral
MACD-0.05Below its signal lineBearish
Stochastic17.4Near the bottom of its rangeOversold
ADX (14)30.7Trending down
Williams %R-57.9Oversold below −80, overbought above −20Neutral
CCI (20)-116.5Oversold below −100, overbought above 100Oversold
Rate of change−12.0%Change over 10 sessionsBearish
ATR (14)$0.05Typical daily range, 11.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for APRE

What happened before

See how APRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow APRE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How APRE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in APRE in the last 90 days.

Loading…

See today’s whale options flow across the market →

APRE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲13 buying vs 11 selling
  • ▲Held by funds +5.5 pts
  • ▲Funds holding +1
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2928+3.6%
In funds' top 1000–
Held by funds23.6%18.2%+5.5 pts
New / increased6 / 78 / 6−7.1%
Reduced / sold out5 / 65 / 2+57.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See APRE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether APRE is in one of them and how their past APRE trades turned out.

APRE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered APRE in an article yet. Here's the latest on the wider market.

About Aprea Therapeutics

Aprea Therapeutics is a pharmaceutical company based in Doylestown, Pennsylvania, that develops cancer drugs. It focuses on treatments designed to target specific genetic mutations found in certain tumors. Its lead candidates are small molecule drugs, APR-1051, a WEE1 inhibitor, and ATRN-119, an ATR inhibitor, which are in clinical trials. The company aims these treatments at patients whose cancers carry particular mutations, and its drugs are still in development.

Headquarters
Doylestown, PA